Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Call Transcript

Ian Mortimer: Sure. I can take the first part and then, Sherry, if you can answer on some of the upcoming milestones. So, I think that’s a better question for Neurocrine than for us. I think I mentioned earlier, the Phase 2 study in focal onset seizures that they’re running is a smaller study than we ran in our Phase 2b X-TOLE study quite significantly smaller. So, I think it’s more of a proof-of-concept study where they’re going to be generating important data over a dose range. But I’m not — where we sit today, I’m not sure there’s a specific kind of go-no criteria or how we think about success. Again, I think it’s good we’re going to have to let Neurocrine unblind that data, obviously share it publicly, and then them to describe what they think the next steps are for the drug.

Sherry Aulin: Yes. And then on the specific study, if it reads out positive, would be eligible for a $15 million milestone payment we are eligible for additional milestone payments through the remainder of clinical development and then obviously, upon certain regulatory-based milestones and the sales-based milestones and royalties.

Rohit Bhasin: Thank you.

Operator: I would now like to turn the call over to Sherry Aulin for closing remarks.

Sherry Aulin: Thank you, everyone, for joining us on the call today. Operator, you may now end the call.

Operator: Thank you, ladies and gentlemen. This does conclude today’s call. Thank you for your participation. You may now disconnect.